20,20-ethane-1,2-diyldioxy-pregn-5-en-3-ol | 2415-36-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 20,20-ethane-1,2-diyldioxy-pregn-5-en-3-ol
• 英文别名: 10,13-dimethyl-17-(2-methyl-1,3-dioxolan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
• CAS: 2415-36-3；21522-50-9
• 化学式: C₂₃H₃₆O₃
• 分子量: 360.537
• InChiKey: SPFIKHYEPDYDPC-UHFFFAOYSA-N

物化性质

• 熔点：
  164-167 °C
• 沸点：
  467.8±45.0 °C(Predicted)
• 密度：
  1.12±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  26
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• 3BÉTA-(BENZYLOXY)-17ALPHA-METHYL-PREGN-5-EN-20-ONE FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS
  申请人：Aelis Farma

  公开号：EP3669876A1

  公开（公告）日：2020-06-24

  The present invention generally relates to a specific pregnenolone derivative for its use for the treatment of a cognitive disorders. More particularly, the invention relates to a compound of Formula (I) for its use in the treatment of cognitive disorders. Indeed, the compound of the invention is in vivo very potent in correcting the cognitive impairments observed in cognitive disorders.

  本发明一般涉及一种特定的孕酮衍生物，用于治疗认知障碍。 更具体地，本发明涉及一种式（I）的化合物 用于治疗认知障碍。 事实上，本发明的化合物在体内非常有效地纠正认知障碍中观察到的认知损伤。
• [EN] 3BETA-(4-METHOXYBENZYLOXY)PREGN-5-EN-20-ONE FOR USE IN THE TREATMENT OF CANNABINOIDS-RELATED DISORDERS<br/>[FR] 3BÊTA-(4-MÉTHOXYBENZYLOXY)PREGN-5-ÉN-20-ONE POUR UNE UTILISATION DANS LE TRAITEMENT DE TROUBLES LIÉS AUX CANNABINOÏDES
  申请人：AELIS FARMA

  公开号：WO2019162328A1

  公开（公告）日：2019-08-29

  The present invention generally relates to a specific pregnenolone derivative for its use for the treatment of a Cannabinoids-Related Disorder. More particularly, the invention relates to a compound of Formula (I), for its use in the treatment of a Cannabinoids-Related Disorder. Indeed, the compound of the invention is in vivo very potent in inhibiting the effects of THC, and is able to inhibit both unconditioned and conditioned effects of THC including THC self-administration and reinstatement in THC seeking in non-human primates.

  本发明一般涉及一种特定的孕酮衍生物，用于治疗大麻素相关障碍。更具体地，该发明涉及一种式（I）的化合物，用于治疗大麻素相关障碍。事实上，该发明的化合物在体内对THC的效果具有很强的抑制作用，并且能够抑制THC的非条件和条件效应，包括THC的自我管理以及在非人类灵长类动物中寻求THC的恢复。
• [EN] 3β-(BENZYLOXY)-17α-METHYL-PREGN-5-EN-20-ONE FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS<br/>[FR] 3β-(BENZYLOXY)-17α-METHYL-PREGN-5-EN-20-ONE DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DE TROUBLES COGNITIFS
  申请人：AELIS FARMA

  公开号：WO2020127468A1

  公开（公告）日：2020-06-25

  The present invention generally relates to a specific pregnenolone derivative for its use for the treatment of a cognitive disorders. More particularly, the invention relates to a compound of Formula (I) for its use in the treatment of cognitive disorders. Indeed, the compound of the inventionis in vivo very potent in correcting the cognitive impairments observed in cognitive disorders.